NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.
Don't have an account? Register
ADVERTISEMENT
ADVERTISEMENT
Small-molecule drugs are beneficial to patients with IBD, however more data is needed around the treatment, the ISG/USG Summer Meeting heard.
Consultant Gastroenterologist at the University Hospital Leuven in Belgium, Prof Séverine Vermeire, delivered a virtual presentation at the ISG/USG Summer Meeting. After two decades of using biological drugs (biologics) to treat inflammatory bowel disease (IBD), small molecule drugs are now entering the therapeutic landscape, according to the Professor.
“For me, they are very welcome additional treatment options that I think are really great assets for our patients with IBD,” she said.
When comparing small molecule drugs with biologics, Prof Vermeire said: “I think it’s fair to say that all of these agents are in the same efficacy range, [as] our biologics. Are they worse? Certainly not. Are they better? I think we cannot say at the moment.”
According to Prof Vermeire, there is a lack of data comparing small molecules and biologics.
“We do not have head-to-head trials comparing our small molecules with biologics,” she said. “We also lack meta-analyses. We have no, or very few, real-world data.
“I think all of these will be needed in the coming years to help us [in] positioning these agents.”
However, Prof Vermeire highlighted some progress being made towards gaining more information.
For example, a 2022 study in the Clinical Gastroenterology and Hepatology journal, found tofacitinib, a small molecule drug, was more effective than vedolizumab, a biologic.
“I think it’s a whole combination of real-world data, personal experience, getting comfortable with the medication, and then balancing the benefits and the risks,” Prof Vermeire said. “And you really need to consider the individual patient profile.”
To conclude her presentation, Prof Vermeire gave her personal opinion on what could be considered the ‘perfect’ ulcerative colitis patient to receive small molecule drugs.
They would be a compliant male or female (who should have no imminent wish for pregnancy); they should also be fit; and preferably under 60 years old. They can be biologic-naive, but can also have taken anti-tumour necrosis factor (anti-TNF) drugs prior.
“I think we should prescribe them [small molecules] as a monotherapy,” the professor concluded.
All-Ireland Gastroenterology, Summer Meeting (ISG/USG), Europa Hotel, Belfast, 9-10 June 2022.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Later in the day, there were two sessions on alcohol misuse and health consequences. Dr Audrey...
Obstetric care for women with rheumatic musculoskeletal disease (RMD) was the key theme of this year’s...
ADVERTISEMENT
There is a lot of publicity given to the Volkswagen Golf, which is celebrating 50 years...
As older doctors retire, a new generation has arrived with different professional and personal priorities. Around...
Catherine Reily examines the growing pressures in laboratory medicine and the potential solutions,with a special focus...
The highlight of this year’s Irish Society for Rheumatology (ISR) Autumn Meeting was undoubtedly the...
ADVERTISEMENT
ADVERTISEMENT
Leave a Reply
You must be logged in to post a comment.